The role of chemotherapy in the treatment of bone and soft tissue sarcomas

Alessandra Longhi, Elisabetta Setola, Michela Versari, Gaetano Bacci

Research output: Contribution to journalArticlepeer-review


While surgery remains the cornerstone of treatment of bone and soft tissue sarcomas, chemotherapy has improved the 5-year overall survival in osteosarcoma and Ewing's sarcoma from 10% to 70% in localized disease. Patients with metastases at presentation treated with surgery combined with chemotherapy have a 3-year survival of 30-50%, but cure is still rare. The role of adjuvant chemotherapy in soft tissue sarcoma has yet to be determined, but it is likely that some patients will benefit. As some bone sarcomas do not respond to chemotherapy, surgery remains the only effective treatment, and there are no effective drugs to treat relapsing patients. Radiotherapy has both a curative role in combination with chemotherapy in soft tissue and Ewing's sarcoma and a palliative role in the other sarcomas.

Original languageEnglish
Pages (from-to)119-126
Number of pages8
JournalCurrent Orthopaedics
Issue number2
Publication statusPublished - Apr 2005


  • Bone
  • Chemotherapy
  • Sarcomas
  • Soft tissue

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine


Dive into the research topics of 'The role of chemotherapy in the treatment of bone and soft tissue sarcomas'. Together they form a unique fingerprint.

Cite this